Nova Mentis Life Sciences Corp has announced that the European Medicines Agency has granted it an Orphan Drug Designations for its novel psilocybin drug for fragile X syndrome treatment. FXS is the main genetic cause of autism spectrum disorder related symptoms.
Companies Featured
Nova MentisNova Mentis is a Canadian listed (CSE, FSE) company that holds two subsidiaries, Nova Mentis Biotech and Pilz BioSciences that investigate psychedelics as medicines for a variety of mental health indicators.